Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus

P. Wei, P. R. Grimm, D. C. Settles, C. R. Balwanz, B. J. Padanilam, S. C. Sansom

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Statins may confer renal protection in a variety of glomerular diseases, including diabetic nephropathy (DN). However, various glomerular lesions have different etiologies and may have different responses to statins. This study was performed to determine the differential effects of simvastatin (SMV) on glomerular pathology including mesangial expansion and podocyte injury in a mouse model of early stage type 2 diabetes mellitus (DM). Type 2 DM was induced in male C57BL6 mice by feeding a high fat diet (HF; 45 kcal fat). After 22 weeks, one group of HF mice was treated with SMV (HF-SMV; 7 μgdayg BW) and another group was treated with vehicle (HF-vehicle) for 4 weeks via osmotic mini-pump. A third group served as age-matched normal diet vehicle controls (ND-vehicle; 10 kcal fat). At the end of treatment, glomerular morphology was evaluated in a blind manner to determine the progression of DN. Body weight, blood glucose, insulin, HDL-cholesterol and triglycerides, but not LDL-cholesterol, were increased in HF mice. Over the course of treatment, the 24-hour urinary albumin excretion (UAE) was unchanged in ND-vehicle. HF mice exhibited elevated UAE, which decreased with SMV, but was unchanged with vehicle. The absolute mesangial volume and the relative mesangial volume per glomerular volume increased in HF-vehicle and remained elevated with SMV treatment. The immuno-staining of nephrin, a protein marker of the integrity of podocyte slit diaphragms, was decreased in HF-vehicle; however, the nephrin quantity of the HF-SMV group was not different from ND-vehicle. It is concluded that SMV reverses podocyte damage, but does not affect mesangial expansion in the kidneys of early stage proteinuria of type 2 DM.

Original languageEnglish (US)
Pages (from-to)503-513
Number of pages11
JournalRenal Failure
Volume31
Issue number6
DOIs
StatePublished - Dec 30 2009

Fingerprint

Podocytes
Simvastatin
Type 2 Diabetes Mellitus
Wounds and Injuries
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Diabetic Nephropathies
Albumins
Fats
Kidney
High Fat Diet
Diaphragm
Proteinuria
LDL Cholesterol
HDL Cholesterol
Blood Glucose
Triglycerides
Body Weight
Insulin
Pathology
Staining and Labeling

Keywords

  • Albuminuria
  • Diabetic nephropathy
  • Mice
  • Simvastatin
  • Statins

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Nephrology

Cite this

Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus. / Wei, P.; Grimm, P. R.; Settles, D. C.; Balwanz, C. R.; Padanilam, B. J.; Sansom, S. C.

In: Renal Failure, Vol. 31, No. 6, 30.12.2009, p. 503-513.

Research output: Contribution to journalArticle

Wei, P. ; Grimm, P. R. ; Settles, D. C. ; Balwanz, C. R. ; Padanilam, B. J. ; Sansom, S. C. / Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus. In: Renal Failure. 2009 ; Vol. 31, No. 6. pp. 503-513.
@article{0b76b65908544d1896dfbd59fda0d754,
title = "Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus",
abstract = "Statins may confer renal protection in a variety of glomerular diseases, including diabetic nephropathy (DN). However, various glomerular lesions have different etiologies and may have different responses to statins. This study was performed to determine the differential effects of simvastatin (SMV) on glomerular pathology including mesangial expansion and podocyte injury in a mouse model of early stage type 2 diabetes mellitus (DM). Type 2 DM was induced in male C57BL6 mice by feeding a high fat diet (HF; 45 kcal fat). After 22 weeks, one group of HF mice was treated with SMV (HF-SMV; 7 μgdayg BW) and another group was treated with vehicle (HF-vehicle) for 4 weeks via osmotic mini-pump. A third group served as age-matched normal diet vehicle controls (ND-vehicle; 10 kcal fat). At the end of treatment, glomerular morphology was evaluated in a blind manner to determine the progression of DN. Body weight, blood glucose, insulin, HDL-cholesterol and triglycerides, but not LDL-cholesterol, were increased in HF mice. Over the course of treatment, the 24-hour urinary albumin excretion (UAE) was unchanged in ND-vehicle. HF mice exhibited elevated UAE, which decreased with SMV, but was unchanged with vehicle. The absolute mesangial volume and the relative mesangial volume per glomerular volume increased in HF-vehicle and remained elevated with SMV treatment. The immuno-staining of nephrin, a protein marker of the integrity of podocyte slit diaphragms, was decreased in HF-vehicle; however, the nephrin quantity of the HF-SMV group was not different from ND-vehicle. It is concluded that SMV reverses podocyte damage, but does not affect mesangial expansion in the kidneys of early stage proteinuria of type 2 DM.",
keywords = "Albuminuria, Diabetic nephropathy, Mice, Simvastatin, Statins",
author = "P. Wei and Grimm, {P. R.} and Settles, {D. C.} and Balwanz, {C. R.} and Padanilam, {B. J.} and Sansom, {S. C.}",
year = "2009",
month = "12",
day = "30",
doi = "10.1080/08860220902963848",
language = "English (US)",
volume = "31",
pages = "503--513",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus

AU - Wei, P.

AU - Grimm, P. R.

AU - Settles, D. C.

AU - Balwanz, C. R.

AU - Padanilam, B. J.

AU - Sansom, S. C.

PY - 2009/12/30

Y1 - 2009/12/30

N2 - Statins may confer renal protection in a variety of glomerular diseases, including diabetic nephropathy (DN). However, various glomerular lesions have different etiologies and may have different responses to statins. This study was performed to determine the differential effects of simvastatin (SMV) on glomerular pathology including mesangial expansion and podocyte injury in a mouse model of early stage type 2 diabetes mellitus (DM). Type 2 DM was induced in male C57BL6 mice by feeding a high fat diet (HF; 45 kcal fat). After 22 weeks, one group of HF mice was treated with SMV (HF-SMV; 7 μgdayg BW) and another group was treated with vehicle (HF-vehicle) for 4 weeks via osmotic mini-pump. A third group served as age-matched normal diet vehicle controls (ND-vehicle; 10 kcal fat). At the end of treatment, glomerular morphology was evaluated in a blind manner to determine the progression of DN. Body weight, blood glucose, insulin, HDL-cholesterol and triglycerides, but not LDL-cholesterol, were increased in HF mice. Over the course of treatment, the 24-hour urinary albumin excretion (UAE) was unchanged in ND-vehicle. HF mice exhibited elevated UAE, which decreased with SMV, but was unchanged with vehicle. The absolute mesangial volume and the relative mesangial volume per glomerular volume increased in HF-vehicle and remained elevated with SMV treatment. The immuno-staining of nephrin, a protein marker of the integrity of podocyte slit diaphragms, was decreased in HF-vehicle; however, the nephrin quantity of the HF-SMV group was not different from ND-vehicle. It is concluded that SMV reverses podocyte damage, but does not affect mesangial expansion in the kidneys of early stage proteinuria of type 2 DM.

AB - Statins may confer renal protection in a variety of glomerular diseases, including diabetic nephropathy (DN). However, various glomerular lesions have different etiologies and may have different responses to statins. This study was performed to determine the differential effects of simvastatin (SMV) on glomerular pathology including mesangial expansion and podocyte injury in a mouse model of early stage type 2 diabetes mellitus (DM). Type 2 DM was induced in male C57BL6 mice by feeding a high fat diet (HF; 45 kcal fat). After 22 weeks, one group of HF mice was treated with SMV (HF-SMV; 7 μgdayg BW) and another group was treated with vehicle (HF-vehicle) for 4 weeks via osmotic mini-pump. A third group served as age-matched normal diet vehicle controls (ND-vehicle; 10 kcal fat). At the end of treatment, glomerular morphology was evaluated in a blind manner to determine the progression of DN. Body weight, blood glucose, insulin, HDL-cholesterol and triglycerides, but not LDL-cholesterol, were increased in HF mice. Over the course of treatment, the 24-hour urinary albumin excretion (UAE) was unchanged in ND-vehicle. HF mice exhibited elevated UAE, which decreased with SMV, but was unchanged with vehicle. The absolute mesangial volume and the relative mesangial volume per glomerular volume increased in HF-vehicle and remained elevated with SMV treatment. The immuno-staining of nephrin, a protein marker of the integrity of podocyte slit diaphragms, was decreased in HF-vehicle; however, the nephrin quantity of the HF-SMV group was not different from ND-vehicle. It is concluded that SMV reverses podocyte damage, but does not affect mesangial expansion in the kidneys of early stage proteinuria of type 2 DM.

KW - Albuminuria

KW - Diabetic nephropathy

KW - Mice

KW - Simvastatin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=72649085468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649085468&partnerID=8YFLogxK

U2 - 10.1080/08860220902963848

DO - 10.1080/08860220902963848

M3 - Article

C2 - 19839828

AN - SCOPUS:72649085468

VL - 31

SP - 503

EP - 513

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 6

ER -